Oxford Cancer Analytics

Oxford Cancer Analytics (OXcan)'s mission is to revolutionize the early detection and management of cancer to impact the lives of millions worldwide. OXcan's multidisciplinary team is developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and interpretable machine learning methods, which can detect the most lethal cancers early when they are still curable. This blood test can be performed affordably, minimally invasively, and routinely, offering exceptional accuracy and localization capabilities across large populations. OXcan has begun applying its biomarker discovery and validation platform to lung cancer, the leading cause of global cancer mortality, and has achieved ISO13485 certification status.